Dyne Therapeutics (DYN) Short term Debt (2025)

Dyne Therapeutics' (DYN) quarterly Short term Debt came in at $67.1 million in Q4 2025.

Dyne Therapeutics (DYN) Short term Debt (2025) Analysis & Trends

Dyne Therapeutics (DYN) has 1 years of Short term Debt data on file, last reported at $67.1 million in Q4 2025.

On a quarterly basis, Short term Debt changed N/A year-over-year to $67.1 million in Q4 2025; TTM through Dec 2025 was $67.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $67.1 million, changed N/A from the prior year.
Short term Debt for Q4 2025 stood at $67.1 million.
Over the last five years, Short term Debt for DYN reached as high as $67.1 million in Q4 2025 and fell as low as $67.1 million in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Dyne Therapeutics	3.94 Bn	3.94 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2025	67.13 Mn